N@N

Josh Schimmer Initiated (BBIO) at Buy and Held Target at $50 on, Oct 24th, 2023

Josh Schimmer of Cantor Fitzgerald, Initiated "BridgeBio Pharma, Inc." (BBIO) at Buy and Held Target at $50 on, Oct 24th, 2023.

Josh has made no other calls on BBIO in the last 4 months.

There are 5 other peers that have a rating on BBIO. Out of the 5 peers that are also analyzing BBIO, 1 agrees with Josh's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Eun Yang of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $33 on, Tuesday, July 18th, 2023

These are the ratings of the 4 analyists that currently disagree with Josh

---

• Salim Syed of "Mizuho" Reiterated at Strong Buy and Held Target at $60 on, Monday, August 28th, 2023
• Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $38 on, Thursday, August 17th, 2023
• Dane Leone of "Raymond James" Maintained at Buy with Increased Target to $46 on, Tuesday, July 18th, 2023
• Paul Choi of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $50 on, Tuesday, July 18th, 2023

Contributing Sources

---